<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04174664</url>
  </required_header>
  <id_info>
    <org_study_id>GO 19/817</org_study_id>
    <nct_id>NCT04174664</nct_id>
  </id_info>
  <brief_title>Comparison of Different Functional Capacity Tests in Cystic Fibrosis Patients With Acute Pulmonary Exacerbation</brief_title>
  <official_title>Comparison of Different Functional Capacity Tests in Cystic Fibrosis Patients With Acute Pulmonary Exacerbation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hacettepe University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hacettepe University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study to investigate and compare functional capacity with different tests and
      to evaluate the relationship between functional capacity and quality of life during acute
      pulmonary exacerbation in children with cystic fibrosis.

      Exercise tests associated with prognostic values in CF patients and decreased exercise
      capacity has been correlated with a reduction in health-related quality of life. Pulmonary
      functions, functional capacity and quality of life will examine in this study.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will be participated children with cystic fibrosis who will diagnosed acute
      pulmonary exacerbation. Patients' pulmonary function test, functional capacity will be assess
      and record at hospital admission and hospital discharge and outpatient clinic control.
      Quality of life will be evaluated at only outpatient clinic control .

      Pulmonary function test will be assessed with spirometry, functional capacity will be
      evaluated with 1-minute sit to stand test and 3-minute step test. And quality of life will be
      evaluated Cystic Fibrosis Questionnaire-Revised (CFQ-R).
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 1, 2019</start_date>
  <completion_date type="Anticipated">January 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">January 1, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>1 minute sit to stand test (STS) repetitions</measure>
    <time_frame>November 2019- January 2021</time_frame>
    <description>number of STS completed at hospital admissions, hospital discharge and outpatient time</description>
  </primary_outcome>
  <primary_outcome>
    <measure>3 minute step test</measure>
    <time_frame>November 2019- January 2021</time_frame>
    <description>number of completed step at hospital admissions, hospital discharge and outpatient time</description>
  </primary_outcome>
  <primary_outcome>
    <measure>pulmonary functions</measure>
    <time_frame>November 2019- January 2021</time_frame>
    <description>pulmonary functions assessment via spirometry</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Quality of life assesment</measure>
    <time_frame>November 2019- January 2021</time_frame>
    <description>Cystic Fibrosis Questionnaire-Revised (CFQ-R) included 4 different age. These versions are teen/adult version,child version,parent version for children, preschool version. Scores range from 0 to 100, with higher scores indicating better health. This questionnaire will be filled only once.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maximal heart rate</measure>
    <time_frame>November 2019- January 2021</time_frame>
    <description>maximal heart rate during 3-minute step test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Heart rate</measure>
    <time_frame>November 2019- January 2021</time_frame>
    <description>difference pre and post test heart beat number</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>oxygen saturation</measure>
    <time_frame>November 2019- January 2021</time_frame>
    <description>difference pre and post test percentage of oxygen saturation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>dyspnea</measure>
    <time_frame>November 2019- January 2021</time_frame>
    <description>difference pre and post test breathlessness with Visual Analogue Scale (VAS).Scores range from 0 to 10, with higher scores indicating worse outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>quadriceps fatigue</measure>
    <time_frame>November 2019- January 2021</time_frame>
    <description>difference pre and post test quadriceps fatigue with Visual Analogue Scale (VAS).Scores range from 0 to 10, with higher scores indicating worse outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>fatigue</measure>
    <time_frame>November 2019- January 2021</time_frame>
    <description>difference pre and post test fatigue with Visual Analogue Scale (VAS).Scores range from 0 to 10, with higher scores indicating worse outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>hospitalization frequency</measure>
    <time_frame>1 year</time_frame>
    <description>number of hospitalization per year</description>
  </secondary_outcome>
  <enrollment type="Anticipated">26</enrollment>
  <condition>Cystic Fibrosis in Children</condition>
  <condition>Exercise Capacity</condition>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>1-minute sit to stand test</intervention_name>
    <description>Childrens will complete 1-minute sit to stand test and 3 minute step test and quality of life questionnaire.</description>
    <other_name>3-minute step test</other_name>
    <other_name>Quality of life</other_name>
    <other_name>pulmonary function test</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Acute pulmonary exacerbation in childrens with cystic fibrosis diagnosed according to Fuchs
        criteria.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Childrens with CF diagnosed between 7-18 years of age and hospitalized due to acute
             pulmonary exacerbation will be included in the study.The diagnosis of acute pulmonary
             exacerbation will be established by Fuchs criteria.

        Exclusion Criteria:

          -  Patients with allergic bronchopulmonary aspergillosis (ABPA) who were treated with
             systemic steroid therapy and noninvasive mechanical ventilation support will not be
             included in the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>7 Years</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Naciye Vardar-Yagli, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Hacettepe University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Deniz Inal-Ince, Professor</last_name>
    <role>Study Chair</role>
    <affiliation>Hacettepe University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Melda Saglam, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Hacettepe University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ebru Yalcin, Professor</last_name>
    <role>Study Chair</role>
    <affiliation>Hacettepe University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Dilber Ademhan-Tural, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Hacettepe University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Kubra Kilic, MSc</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hacettepe University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Kübra Kılıç, PhD Student</last_name>
    <phone>+903123051576</phone>
    <email>fztktas@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Hacettepe University</last_name>
    <phone>+903123051576</phone>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hacettepe University</name>
      <address>
        <city>Ankara</city>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kubra Kilic, MsC</last_name>
      <phone>+903123051576</phone>
      <email>fztktas@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Hacettepe University</last_name>
      <phone>+903123051576</phone>
    </contact_backup>
  </location>
  <location_countries>
    <country>Turkey</country>
  </location_countries>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>November 13, 2019</study_first_submitted>
  <study_first_submitted_qc>November 20, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 22, 2019</study_first_posted>
  <last_update_submitted>November 20, 2019</last_update_submitted>
  <last_update_submitted_qc>November 20, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 22, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hacettepe University</investigator_affiliation>
    <investigator_full_name>Kübra Kılıç</investigator_full_name>
    <investigator_title>MSc, PT</investigator_title>
  </responsible_party>
  <keyword>pulmonary exacerbation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cystic Fibrosis</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

